Application of PLX3397 in treatment of colorectal cancer

A PLX3397, 1. The technology of PLX3397, applied in the field of PLX3397 in the treatment of colorectal cancer, can solve the problems of low toxicity and side effects, unavailable drugs, insensitivity to chemotherapy drugs, etc., achieve low toxicity and side effects, reduce liver metastasis, and inhibit malignant proliferation Effect

Pending Publication Date: 2022-07-01
THE SIXTH AFFILIATED HOSPITAL OF SUN YAT SEN UNIV
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

(2) TAMs in the tumor microenvironment of CRC can also make tumor cells less sensitive to chemotherapeutic drugs
[0006] The first CSF1R-targeting inhibitor pexidartinib ((PLX3397, trade name: Turalio)) developed by the Japanese pharmaceutical company Daiichi Sankyo Co., Ltd. has been approved by the US FDA in 2019 as a specific drug for tenosynovial giant cell tumor ( Tenosynovial giant cell tumor (TGCT) has good curative effect and low side effects, but there is no report on the application of this drug in the treatment of mCRC.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of PLX3397 in treatment of colorectal cancer
  • Application of PLX3397 in treatment of colorectal cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] Example 1 Therapeutic effect of CSF1R inhibitor PLX3397 on MSS subtype CRC

[0031] 1. Experimental steps

[0032] (1) Construction, administration and monitoring of CT26 subcutaneous xenografts of MSS subtype CRC cells

[0033] BALB / C mice (male, 6-8 weeks old, body weight 20-25 g) were anesthetized with pentobarbitone (50 mg / kg), the dorsal inoculation site of the mice was shaved, and each mouse was inoculated subcutaneously with 1 ×10 6 CT26 cells, when the tumor grows to about 100-150mm3 were randomly divided into 5 groups [3 different doses of PLX3397 group, 5-fluorouracil (5-FU) control group, PLX3397 and 5-FU combined administration group], 6-7 animals in each group. Among them, PLX3397 was dissolved in an aqueous solution containing 5% DMSO and 25% PEG300 to prepare a dosing solution [weigh an appropriate amount of PLX3397 powder, dissolve it in DMSO (5% of the final volume), and then add PEG300 and mix (25% of the final volume). ), and finally add sterile wa...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the technical field of medicines, particularly relates to application of PLX3397 in treatment of colorectal cancer, and discloses novel application of PLX3397, namely application of PLX3397 in treatment of colorectal cancer. Research finds that oral administration of PLX3397 can significantly inhibit malignant proliferation of subcutaneous transplanted tumor of colorectal cancer, and also can significantly reduce liver metastasis of colorectal cancer, and the combination of PLX3397 and 5-FU can achieve a combined synergistic effect. The PLX3397 can be prepared into the medicine for treating the colorectal cancer, or the medicine for inhibiting the proliferation of the colorectal cancer cells, or the medicine for reducing the liver metastasis of the colorectal cancer cells. Meanwhile, the PLX3397 has low toxic and side effects when being used for treating the colorectal cancer, so that a new way and a new direction are provided for treatment of the colorectal cancer, and the PLX3397 has important application value.

Description

technical field [0001] The invention belongs to the technical field of medicine, in particular to the use of PLX3397 in the treatment of colorectal cancer. Background technique [0002] Colorectal cancer (CRC) is one of the most common malignant tumors, with the third highest incidence among all malignant tumors. Due to the low popularity of early screening such as colonoscopy, more than 35% of the patients have developed distant metastasis at the initial diagnosis and lost the chance of radical resection. They can only choose systemic systemic therapy to prolong their survival. Among them, chemotherapy is one of the standard treatment regimens for metastatic colorectal cancer (metastatic CRC, mCRC). The commonly used chemotherapy regimens are mainly 5-fluorouracil (5-FU), oxaliplatin or irinotecan. However, due to the high toxicity and intolerance of this regimen, it is difficult to break through the overall survival of chemotherapy. [0003] PD1 / PD-L1 immunotherapy has b...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/444A61P35/00A61P35/04A61K31/513
CPCA61K31/444A61P35/00A61P35/04A61K31/513A61K2300/00
Inventor 李英杰骆衍新朱铭轩白亮亮彭绍勇王小琳禹汇川刘晓霞黄美近
Owner THE SIXTH AFFILIATED HOSPITAL OF SUN YAT SEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap